Commitments and Contingencies The Companys long-term contractual obligations include commitments and estimated purchase obligations entered into in the normal course of business. These obligations include commitments related to purchases of inventory of our products, research and development service agreements, income tax contingencies, operating leases, selling, general and administrative obligations, leased office space for our principal office in Parsippany, New Jersey and additional leased office space in San Diego, California, royalties, milestone payments and other contingent payments due under the Companys license and acquisition agreements. Future estimated contractual obligations as of December31, 2016 are: Contractual Obligations (1) Less Than 1 Year 1-3 Years 3-5 Years More Than 5 Years Total (In thousands) Inventory related commitments $ 17,945 $  $  $  $ 17,945 Research and development 41,330 12,175 523 124 54,152 Operating leases 7,213 14,569 14,811 33,729 70,322 Selling, general and administrative 6,947 2,008 137  9,092 Total contractual obligations $ 73,435 $ 28,752 $ 15,471 $ 33,853 $ 151,511 _______________________________________ (1) This table does not include any milestone and royalty payments which may become payable to third parties for which the timing and likelihood of such payments are not known, as discussed below. It also does not include the long-term debt obligations. See Note 10 Convertible Senior Notes for further details. All of the inventory related commitments included above are non-cancellable. Included within the inventory related commitments above are purchase commitments for 2017 totaling $7.0 million and $8.9 million for Angiomax and Orbactiv bulk drug substances, respectively. Of the total estimated contractual obligations for research and development and selling, general and administrative activities, $29.6 million are non-cancellable. The Company leases its principal offices in Parsippany, New Jersey. The lease covers 173,146 square feet and expires January 202